Geert Cauwenbergh

Dr. Cauwenbergh is President and CEO of RXi Pharmaceuticals, Corp. Prior to this role, he served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development.

Prior to founding Barrier, Dr. Cauwenbergh served as Vice President R&D for Johnson & Johnson’s Skin Research Center where he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies.

He received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.